Sign in
4

Changes in Ownership

Roivant Sciences Ltd. Filed Acc 0001140361-25-038126

President & Immunovant CEO sold 125,667 shares at an average $16.29 ($2,047,336)

  • President & Immunovant CEO acquired 125,667 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Venker Eric · President & Immunovant CEO

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2025-10-09 Exercise or conversion : show line 1 in the form 10b5-1 +104,940 $15.85 $1,663,299 1,609,899 D
2025-10-09 Sale : show line 2 in the form 10b5-1 −104,940 $16.30 $1,710,522 1,504,959 D
2025-10-13 Exercise or conversion : show line 3 in the form 10b5-1 +20,727 $15.85 $328,523 1,525,686 D
2025-10-13 Sale : show line 4 in the form 10b5-1 −20,727 $16.25 $336,814 1,504,959 D
Open-market sales · 125,667 sh · avg $16.29 · $2,047,336

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2025-10-09 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) −104,940 872,110 D
2025-10-13 Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) −20,727 851,383 D
Loading xslF345X05/form4.xml…